In This Article:
As the United States market grapples with mixed performances across major indices, with the S&P 500 and Nasdaq showing slight gains while the Dow Jones Industrial Average tumbles, investors are keeping a close eye on high-growth tech stocks amid concerns about tariffs and economic outlook. In this environment, identifying promising tech stocks requires careful consideration of their adaptability to regulatory changes and their potential for innovation in a rapidly evolving sector.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 20.44% | 29.79% | ★★★★★★ |
| Arcutis Biotherapeutics | 25.76% | 58.17% | ★★★★★★ |
| TG Therapeutics | 26.03% | 37.60% | ★★★★★★ |
| Alkami Technology | 20.46% | 85.16% | ★★★★★★ |
| Travere Therapeutics | 28.65% | 66.06% | ★★★★★★ |
| Alnylam Pharmaceuticals | 22.72% | 58.76% | ★★★★★★ |
| TKO Group Holdings | 22.48% | 25.17% | ★★★★★★ |
| AVITA Medical | 27.81% | 55.17% | ★★★★★★ |
| Lumentum Holdings | 21.61% | 120.49% | ★★★★★★ |
| Ascendis Pharma | 32.85% | 59.72% | ★★★★★★ |
Click here to see the full list of 232 stocks from our US High Growth Tech and AI Stocks screener.
Let's explore several standout options from the results in the screener.
GDS Holdings
Simply Wall St Growth Rating: ★★★★☆☆
Overview: GDS Holdings Limited, along with its subsidiaries, focuses on developing and operating data centers in the People's Republic of China and has a market capitalization of approximately $4.01 billion.
Operations: The primary revenue stream for GDS Holdings comes from the design, build-out, and operation of data centers, generating CN¥10.32 billion. The company's focus is on providing infrastructure services within the data center sector in China.
GDS Holdings has demonstrated a significant turnaround, evidenced by its latest financials where quarterly revenue rose to CNY 2.69 billion from CNY 2.47 billion year-over-year, and net income surged to CNY 4.19 billion from a loss of CNY 3.17 billion. This rebound is mirrored in annual figures, with revenue increasing to CNY 10.32 billion and net income flipping to a gain of CNY 3.43 billion from a substantial loss previously. Looking ahead, GDS anticipates revenue growth between 9.4% to 12.3% for the upcoming year, reflecting optimism despite past volatility in earnings and share price fluctuations over recent months.
-
Unlock comprehensive insights into our analysis of GDS Holdings stock in this health report.
-
Explore historical data to track GDS Holdings' performance over time in our Past section.
Rocket Pharmaceuticals
Simply Wall St Growth Rating: ★★★★★☆
Overview: Rocket Pharmaceuticals, Inc. is a late-stage biotechnology company developing gene therapies for rare and devastating diseases in the United States, with a market cap of $696.29 million.